Glass House Brands (GLAS) Return on Sales (2020 - 2026)

Glass House Brands (GLAS) posted quarterly Return on Sales of 0.0% for Q1 2026, down 5.22% quarter-over-quarter from 0.0% in Q4 2025.

Glass House Brands (GLAS) Return on Sales (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported Return on Sales for 7 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.

In Q1 2026, Return on Sales changed N/A year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed N/A YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
Return on Sales eased to 0.0% in Q1 2026 per GLAS's latest filing, from 0.0% in the prior quarter.
Across five years, Return on Sales topped out at 0.01% in Q3 2022 and bottomed at 7563.56% in Q2 2022.
Historically, Return on Sales has averaged 1196.51% across 5 years, with a median of 0.0% in 2026.
Annual changes were most pronounced in 2022 — Return on Sales plunged 756355 bps — and 2024, when it soared 440153 bps.
Glass House Brands' Return on Sales stood at 0.01% in 2022, then sank by 46363696 bps to 4401.52% in 2023, then jumped by 100 bps to 0.0% in 2024, then slumped by 314 bps to 0.0% in 2025, then declined by 5 bps to 0.0% in 2026.
Business Quant data shows GLAS's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn	0.00%
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn	0.00%
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn	0.00%
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn	0.00%
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	0.00%
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn	0.00%
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	0.00%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Glass House Brands	825.81 Mn	807.26 Mn	15.77 Mn	0.00%

Download Data